Keros Therapeutics Director Jean Jacques Bienaime buys USD 10,610 in common shares
KROS•Director buys 1,000 Keros Therapeutics shares
Keros Therapeutics director Jean Jacques Bienaime bought 1,000 common shares at a weighted-average price of USD 10.61.
His direct holding rose to 18,592 shares following the purchase.
